Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Recursion Pharmaceuticals Inc Cl A (RXRX)

Recursion Pharmaceuticals Inc Cl A (RXRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,178,813
  • Shares Outstanding, K 406,495
  • Annual Sales, $ 58,840 K
  • Annual Income, $ -463,660 K
  • EBIT $ -574 M
  • EBITDA $ -538 M
  • 60-Month Beta 0.91
  • Price/Sales 34.06
  • Price/Cash Flow N/A
  • Price/Book 2.15

Options Overview Details

View History
  • Implied Volatility 153.22% ( +49.00%)
  • Historical Volatility 90.55%
  • IV Percentile 97%
  • IV Rank 61.71%
  • IV High 206.11% on 11/29/24
  • IV Low 67.98% on 09/24/24
  • Put/Call Vol Ratio 0.07
  • Today's Volume 35,724
  • Volume Avg (30-Day) 20,108
  • Put/Call OI Ratio 0.46
  • Today's Open Interest 392,895
  • Open Int (30-Day) 405,202

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.34
  • Number of Estimates 3
  • High Estimate -0.27
  • Low Estimate -0.39
  • Prior Year -0.40
  • Growth Rate Est. (year over year) +15.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.72 +18.43%
on 06/23/25
6.07 -7.91%
on 06/10/25
+0.22 (+4.10%)
since 06/09/25
3-Month
3.96 +41.16%
on 05/23/25
6.11 -8.51%
on 04/23/25
+0.94 (+20.22%)
since 04/09/25
52-Week
3.79 +47.49%
on 04/09/25
12.36 -54.77%
on 02/18/25
-1.85 (-24.87%)
since 07/09/24

Most Recent Stories

More News
10 Under-the-Radar Tech Stocks With Incredible Growth Potential

Just because it's not a household name doesn't mean it's not a magnificent investment.

MELI : 2,477.08 (+0.02%)
CFLT : 25.56 (+0.35%)
FTNT : 107.65 (+0.10%)
TTD : 75.63 (+2.16%)
SNOW : 221.90 (-0.72%)
TYL : 578.98 (-1.04%)
DOCN : 29.83 (+1.26%)
RXRX : 5.59 (+4.29%)
RGTI : 13.51 (+0.97%)
MRVL : 72.26 (+0.43%)
Here's Why Shares in Recursion Pharmaceuticals Surged Today

RLYB : 0.4464 (-12.71%)
RXRX : 5.59 (+4.29%)
Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia

RXRX : 5.59 (+4.29%)
The Hottest 10 Artificial Intelligence (AI) Stocks on the Market

This group of companies reflects most of the industry's past, present, and future.

MSFT : 503.51 (+1.39%)
BABA : 103.83 (-3.85%)
NVDA : 162.88 (+1.80%)
GOOGL : 176.62 (+1.30%)
GOOG : 177.66 (+1.43%)
IBM : 290.14 (-0.10%)
AI : 27.39 (+3.87%)
RXRX : 5.59 (+4.29%)
IONQ : 45.56 (+1.31%)
MRVL : 72.26 (+0.43%)
PLTR : 143.13 (+2.45%)
Will RXRX's Shift in Pipeline Focus Help Restore Investor Faith?

Recursion Pharmaceuticals RXRX faced a massive setback in May 2025 after announcing the discontinuation of three key drug candidates — REC-994, REC-2282 and REC-3964 — due to disappointing results...

RLAY : 3.81 (+6.13%)
SDGR : 21.68 (+1.24%)
RXRX : 5.59 (+4.29%)
Doctors Are Being Outpaced by AI-Powered Algorithms — Here’s What It Means for Investors

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:MSFT),(NASDAQ:ASTH),(NASDAQ:RXRX),(NASDAQ:MDAI) EQNX::TICKER_END

MSFT : 503.51 (+1.39%)
AVAI : 0.5358 (-5.34%)
ASTH : 24.82 (+1.43%)
RXRX : 5.59 (+4.29%)
MDAI : 3.14 (+10.56%)
ACN : 297.40 (-1.95%)
Doctors Are Being Outpaced by AI-Powered Algorithms -- Here's What It Means for Investors

/CNW/ -- USA News Group News Commentary – This week in Geneva, the World Health Organization (WHO) is hosting a workshop titled "Enabling AI for Health...

MSFT : 503.51 (+1.39%)
AVAI : 0.5358 (-5.34%)
ASTH : 24.82 (+1.43%)
RXRX : 5.59 (+4.29%)
MDAI : 3.14 (+10.56%)
ACN : 297.40 (-1.95%)
Can RXRX's AI-Based Approach Revolutionize the Drug Discovery Process?

Recursion Pharmaceuticals RXRX is redefining the traditional model of drug discovery by harnessing the power of artificial intelligence (AI) through its proprietary RecursionOS platform, developed in...

RLAY : 3.81 (+6.13%)
SDGR : 21.68 (+1.24%)
RXRX : 5.59 (+4.29%)
AI Is Quietly Reinventing Healthcare--And Real Deployments Are Now Underway

/CNW/ -- Several experts are seeing that value of AI's total overhaul of healthcare, including beneficial additions such as generative AI apps demonstrating...

AVAI : 0.5358 (-5.34%)
RXRX : 5.59 (+4.29%)
TEM : 58.41 (-0.17%)
OABI : 2.20 (+6.28%)
TVGN : 1.2400 (+1.64%)
Why This Wildcard Stock Could Be a Future Star

Recursion’s slow and steady start could lead to a bright future in biotech.

NVDA : 162.88 (+1.80%)
RXRX : 5.59 (+4.29%)
RHHBY : 40.8700 (+1.95%)
SNY : 48.83 (+1.35%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science and engineering. Recursion Pharmaceuticals Inc. is based in SALT LAKE CITY.

See More

Key Turning Points

3rd Resistance Point 6.10
2nd Resistance Point 5.94
1st Resistance Point 5.76
Last Price 5.59
1st Support Level 5.42
2nd Support Level 5.26
3rd Support Level 5.08

See More

52-Week High 12.36
Fibonacci 61.8% 9.09
Fibonacci 50% 8.07
Fibonacci 38.2% 7.06
Last Price 5.59
52-Week Low 3.79

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar